Clinical study, NCT03373188 is a randomized phase I trial evaluating the efficacy of anti-semaphorin 4D (anti-SEMA4D) monoclonal antibody VX15/2503 with and without ipilimumab or nivolumab in treating patients with stage I-III pancreatic cancer that is resectable or locally advanced. The gene discussed is SEMA4D; the disease is familial pancreatic carcinoma.